Objective: We aimed to evaluate the capacity of measuring serum anti-mullerian hormone (AMH) levels in determining ovarian reserve in patients with polycystic ovary syndrome (PCOS) with increased ovarian reserve and in premenopausal women with decreased ovarian reserve.
INTRODUCTION
Ovarian reserve is an important marker that is related to the number and quality of oocyte, reflecting the reproductive capacity of a woman. Follicle-stimulating hormone (FSH) and estradiol (E2) values measured on the 3 rd day of spontaneous period are indirect markers showing ovarian reserve (1); therefore, provocative tests, such as clomiphene citrate challenge test and GNRH agonist stimulation test were developed (2) . Recently, ultrasound assessment of ovarian volume and total antral follicle count (AFC) were also found to be useful in predicting ovarian responses. Studies are ongoing to find better biomarkers in determining ovarian reserve. Anti-müllerian hormone (AMH), activin, follistatin, and inhibin b can be regarded among candidate biomarkers (1, 3) .
Anti-müllerian hormone is a dimeric glycoprotein. It is composed of two 72-kDa monomers linked by disulfide bridges (4, 5) . AMH belongs to the transforming growth factor beta family, which includes the inhibin and activin glycoproteins (6) . AMH is secreted by primary, pre-antral, and antral follicles. It is expressed in granulosa cells of the follicle and secreted independently from FSH (7) . As the follicle enlarges, secretion decreases. (8) . Since AMH is both independent from the menstrual cycle and highly correlated with the pre-antral follicle number, its importance in determining ovarian reserve has begun to be understood increasingly in recent years (4, 5) .
Polycystic ovary syndrome (PCOS), seen approximately in 4%-12% of women in the reproductive age group, is the most frequently encountered reproductive endocrinopathy in women (9, 10) . There is a parallel correlation between antral follicle number and serum AMH in women with polycystic ovary syndrome (11) . Elevated AMH values in either serum or follicular fluids of patients with PCOS are associated with an increase in immature oocyte number. It is considered that this elevation is related to the increase in number of granulosa cells rather than the number of follicles. Studies have shown that there are 75 times as many granulosa cells in follicles of women with polycystic ovary syndrome than granulosa cells in follicles of women without PCOS (12) .
We aimed to evaluate the capacity of measuring serum AMH levels in determining ovarian reserve in patients with PCOS with increased ovarian reserve and in premenopausal women with decreased ovarian reserve.
METHODS

Study Design and Subjects
This study was performed on total 75 patients comprised of 25 patients aged 20-35 years with PCOS; 25 women in the same age group with normo-ovulatory cycle and 25 patients aged 40-45 years in premenopausal period who presented to the Obstetrics and Gynecology Clinic of İstanbul Medeniyet University Göztepe Training and Research Hospital between May-September 2011.
To rule out the primary infertility, study groups were constituted from women who gave their first births earlier.
PCOS diagnosis was made based on the "2003 Rotterdam Consensus Conference on PCO" (ESHRE ASRM) criteria: 1-menstrual irregularities (oligo/amenorrhea, oligo/anovulation), 2-clinical and/or biochemical hyperandrogenism and 3-ultrasonographic PCO morphology (13) . Presence of at least two of these three criteria and being able to rule out diseases such as congenital adrenal hyperplasia, Cushing syndrome, and androgen-secreting tumor was considered to be sufficient for a diagnosis. Presence of at least two of these three criteria and being able to rule out diseases such as congenital adrenal hyperplasia, Cushing syndrome and androgen-secreting tumor was considered to be sufficient for PCOS diagnosis. Age, medical history, history of delivery, height, weight, menstrual cycle and gynecologic examinations of patients were recorded before the study. During the first visit, body mass index (BMI) values of patients were calculated in kg/m 2 by measuring their heights (cm) and weights (kg). All of the ultrasonographic examinations were performed in the lithotomy position and by using a 6-8 mHz B mode pelvic and endovaginal probe (Logiq A5; General Electric, Connecticut, USA). Antral follicles were defined as follicles between 2 and 10 millimeters in diameter. Antral follicle count represents the total number of antral follicles from two ovaries. The number of antral follicles, was counted on the third day of the menstrual period Presence of 12 or more follicles with asize of 2-9 mm and/or increased ovary volume (>10 mL) was described to be polycystic ovary. Presence of this finding in one ovary was considered to be sufficient. Distribution of follicles was not taken into consideration in the evaluation of polycystic ovary.
Biochemical Analysis
Blood specimens were taken from all of the patients for FSH, luteinizing hormone (LH), estradiol (E2), and AMH analyses during the early follicular period (on the third day of spontaneous period). Samples were centrifuged for 10 minutes at 4000 rpm after leaving them at room temperature for at most 1 hour. The sera obtained were stored at -20°C until they were analyzed. FSH, LH, and E2 levels were measured on a DXI 800 access analyzer (Beckman Coulter, Indianapolis, USA) by using a chemiluminescent method. AMH level measurement was performed by using ELISA method with the AMH Gen II Elisa Kit (Beckman Coulter, Indianapolis, USA). Intra-and inter-assay CVS of the kit were less than 5%.
Statistical Analysis
The Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) v. 11.5 program was used for statistical analysis. Kolmogorov-Smirnov normality test was used for the distribution of continuous data. During the evaluation of the study data, regarding the intergroup comparisons of the data with parametric distribution as well as descriptive statistical methods (Mean, Standard deviation). Differences at baseline between groups were, when normally distributed, evaluated by ANOVA test, and by the Kruskal-Wallis test, when non-normally distributed. Tukey HSD Test was used for the in-group comparisons of the data. Regarding the data without a parametric distribution, Spearman's rho correlation coefficient was used for analysis of the relationship between parameters when normally distributed and Pearson correlation was used when they were non-normalllly distributed. P-value <0.05 was considered significant.
RESULTS
As a result of this study, we found that there was a significant difference between age, FSH (IU/L), LH (IU/L), AMH (pmol/L), and AFC parameters. There was no statistically significant difference in E2 values between groups (p=0.086) ( Table 1 ).
There was a highly statistically significant difference between the FSH levels of the cases according to the groups (p<0.001).
We determined the mean FSH values of the PCOS, premenopausal, and control groups to be 5.34±1.91 IU/L, 20.39±22.90 IU/L, and 7.36±4.46 IU/L, respectively ( Table 1) . As a consequence of the paired comparisons performed to determine where the difference arose from each group, mean FSH levels of the premenopausal group were determined to be significantly higher than in the PCOS group and control group (p=0.001; p=0.003), and no statistically significant difference was determined between mean FSH levels of the PCOS group and control group (p=0.861) ( Table 2) . (Table 1) . As a consequence of the paired comparisons performed to determine where the difference arose from each group, mean LH levels of the premenopausal group were determined to be significantly higher than in the PCOS group and control group (p=0.045; p=0.013), and no statistically significant difference was determined between mean LH levels of the PCOS group and control group (p=0.856). There was no statistically significant difference between the E2 levels of the cases according to the groups (p=0.086) ( Table 2 ).
There was a highly statistically significant difference between the AMH levels of the cases according to the groups (p<0.001).
We determined the mean AMH values of the PCOS group to be 58.45±33.68pmol/L, 2.47±5.31 pmol/L for the premenopausal group, and 19.92±21.35 pmol/L for the control group (Table 1) . As a consequence of the paired comparisons performed to determine where the difference arose from each group, mean AMH levels of the PCOS group were determined to be significantly higher than in the premenopausal group and the control group (p<0.001; p<0.001). The control group was also determined to be higher than the premenopausal group (p=0.026) ( Table 2 ).
There was a highly statistically significant difference between the AFC of the cases according to the groups (p<0.001). We determined the mean AFC of the PCOS group to be 18.04±3.94, 4.28±1.17 for the premenopausal group, and 8.96±2.15 for the control group ( Table 1) . As a consequence of the paired comparisons performed to determine where the difference arose from each group, mean AFC of the PCOS group was determined to be significantly higher than in the premenopausal group and the control group (p<0.001; p<0.001). The control group was also determined to be higher than the premenopausal group (p<0.001) ( Table 2) .
In all groups, a statistically significant negative correlation was found between AMH and FSH levels (r=-0.579; p<0.001) ( Table 3 , Figure 1 ). Therefore, in the analysis performed including all patients without group discrimination, a statistically significant negative relationship was found between AMH and BMI levels (r=-0.277; p=0.016) ( Table 3 , Figure 2 ). Also, a statistically significant negative correlation was found between AFC and BMI lev- Table 3 ). There was a highly statistically significant positive correlation between AMH and AFC levels (r=0.908; p<0.001) ( Table 3 ), (Figure 3 ).
The AMH reference value was determined in the control group. The median of the control group was 10.56 pmol/L, and this value was used as the reference for all other groups. AMH values were divided into two groups: ≤10.56 pmol/L and >10.56 pmol/L, respectively (Table 4a ). There was no value under 10.56 pmol/L in the PCOS group. All measurements in the PCOS group were above the reference value. There were 13 cases (52%) under 10.56 pmol/L and 12 cases (48%) above 10.56 pmol/L in the control group, and there were 24 cases (96%) under 10.56 pmol/L and 1 case (4%) above 10.56 pmol/L in the premenopausal group. Also, 64.9% of all patients with AMH levels under the reference value were found in the premenopausal group, and the remaining 35.1% was found in the control group (Table 4a) .
To refine the value of the AMH reference range, the first and third quartiles in the median value in the control group measurements were also determined as reference values. The first quartile value was 6245 pmol/L, and the third quartile value was 32.150 pmol/L. According to this, cases that had AMH levels ≤6245 pmol/L; 6245 to 10,560 pmol/L; 10.560 to 32,150 pmol/L, and >32.150 were divided into four groups, respectively. In the PCOS group, 76% of cases (n=19) were found to have higher than 32.150 pmol/L. In the premenopausal group, 84% of cases were found to have under 6245 pmol/L. In the control group, 24% of cases (n=6) were under 6245 pmol/L, 28% of them (n=7) were found between 6245 and 10,560 pmol/L, 24% of them (n=6) were found between 10,560 and 32,150 pmol/L, and 24% of them (n=6) were found above 32.150 pmol/L (Table 4b) .
DISCUSSION
Ovarian reserve depends on two factors: 1-primordial follicle reserve and 2-oocyte quality. Primary follicles develop from the primordial follicle pool, and afterwards, secondary (pre-antral) follicles occur. Those structures compose the antral follicle pool. One follicle has been selected each month for ovulation. AMH is secreted by ovarian granulosa cells of growing pre-antral and small antral follicles (4).
Many authors suggested that antral follicle count, an important marker of ovarian reserve, decreases with advancing age, and correspondingly, serum AMH levels also decrease with advancing age (8, 14) . In our study, we found a statistically significant positive correlation between AMH levels and antral follicle count. We also found a statistically significant negative correlation between age and AMH levels. There is a statistically significant positive correlation between age and FSH levels. We have demonstrated that when the serum levels of FSH are increased, the serum AMH levels decrease concordantly. There are statistically significant differences between AMH and FSH levels of the control and premenopausal groups, who had only an age difference between each other. Comparing AMH and FSH levels in the premenopausal to the control group, we found lower AMH and higher FSH levels for the premenopausal group.
In their study performed by Annemarie De Vet et al. (15) in 41 normo-ovulatory premenopausal and 13 healthy cases in the menopausal period, the authors have suggested that AMH was a good marker showing ovarian aging, considering that AMH production decreased with advancing age (15) . In the study performed by Fanchin et al. (7), the direct and indirect relationships between AMH, antral follicle count, FSH, and inhibin-b hormones were investigated. It was shown that ovarian volume, antral follicle count, and AMH decreased with advancing age, and also, there was the presence of a positive correlation between antral follicle count and AMH. A negative correlation between AMH and FSH production with advancing age was also noted in other studies (14) .
It has been suggested that there is a positive correlation between antral follicle count and serum AMH levels in women with polycystic ovary syndrome. However, it has also been suggested that high levels of AMH in these patients might be related to the increase in the number of granulosa cells rather than the increase in number of follicles (16) . Indeed, in studies performed by Desforges-Bullet and Pellatt, it has been shown that follicular granulosa cell numbers of women with PCOS are 75 fold higher than in women without PCOS (11, 16) . It has been suggested that serum AMH levels of women with PCOS are 2-3-fold higher than serum AMH levels of healthy women in the same age group, and also, the reduction occurring in AMH concentrations with advancing age is more slowly progressing in patients with PCOS (16). In our study, we found a significant difference between PCOS, premenopausal, and control groups regarding AMH levels and AFC. AMH levels and AFC of the PCOS group were significantly higher than in the premenopausal group and the control group. Therefore, patients having PCOS with larger ovarian reserves may be represented in serum with high AMH levels and higher AFC in USG.
In the study performed by Tehrani et al. (17) a total of 174 patients, including 89 normo-ovulatory and 85 PCOS cases, were included. They have shown that serum AMH levels of PCOS cases were statistically significantly higher than in normo-ovulatory healthy individuals. Also, in the study performed by Hudecova et al. (18) in 2009, the authors found that AMH levels and AFC in patients with polycystic ovary syndrome were higher than in the control group, and FSH in patients with polycystic ovary syndrome was less than in the control group. Again, as a consequence of the study performed by Hosseini et al. (19) in 2009, the authors concluded that AMH values in patients with PCOS were higher than in the group without PCOS.
Obesity is an important factor, preventing fertility, impairing normal ovulatory cycles, and increasing abortion rates (20) . Possible causes of this condition are considered to be as follows: obesity affects the pulsatile release of gonadotropin-releasing hormone negatively, and the synthesis of ovarian and adrenal androgens and sex hormone-binding globulin are negatively affected by obesity and insulin resistance in obese individuals (21) . Low levels of AMH and inhibin b values of obese patients in studies performed suggest decreased ovarian reserves in these individuals (20) . During the comparison of AMH and BMI without group discrimination, we found a significant negative correlation between AMH and BMI levels. A similar negative correlation was also found between AFC and BMI levels.
In summary, obesity can be considered an important factor that decreases ovarian reserves and might be associated with the decreased number of successful pregnancies. In a study performed on 290 individuals by Buyuk et al. in 2008 , the authors found that AMH levels of individuals with BMI above 30 kg/m 2 were 65% less than AMH levels of individuals with BMI below 30 kg/m 2 (21) . When all other parameters were neglected, in the statistical analysis performed for BMI alone, it was shown in this study that ovarian reserves and, concordantly, serum AMH levels decreased in obese women (21) . In a study performed by Steiner et al. (22) , the authors divided 330 women aged 18-35 years into two groups according to their BMI: below 25 kg/m 2 and above 30 kg/m 2 . According to these results, they found AMH values to be lower in the obese group at a rate of approximately 34% (2.9±2.1 ng/mL). Thus, the authors demonstrated a negative relationship only between BMI and AMH by ruling out all other characteristics.
CONCLUSION
The result of our study has shown that AMH is a highly reliable marker in determining ovarian reserve. Any pathology affecting ovarian reserve will directly affect serum AMH levels. The most certain proof of this statement is that "a condition like PCOS," which increases the ovarian reserve, has made an elevation in serum AMH levels and that "a factor like obesity," which has affected ovarian reserve negatively, has made a decrease in serum AMH levels. Also, there has been a positive relationship between AMH levels and AFC. The correlation between serum AMH levels and AFC, which is a valuable marker for ovarian reserve, has shown us that AMH can be considered to have an important role in determining ovarian reserve. Whether it is helpful or not to use AMH as a screening tool for PCOS requires future investigations. 
